ISV reshapes the composition of the tumor microenvironment. (A-B) Uniform manifold approximation and projections (UMAPs) of flow cytometry (A) or scRNA-seq (B) data from all tumor samples, colored by cell type (left) or patient (right). Note: patient colors are consistent throughout the article. (C) Reclustering of T-cells from the scRNA-seq data set. Clusters are denoted by color and labeled according to assigned phenotype. (D-E) Baseline gene expression of TLR9 (D) and selected ibrutinib targets (E) for each patient for indicated cell populations. (F) Relative abundance of indicated cell types in the scRNA-seq data set at the injected site in the pretreatment and on-treatment samples. (G) Relative abundance of selected T-cell subpopulations in the scRNA-seq data at the injected tumor site, pretreatment, and on treatment. P values were calculated by paired 2-sided Wilcoxon rank-sum tests for pretreatment (Pre Tx) vs on treatment (Day 8 or Week 6): ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. P values are only shown if P ≤ .05. DC, dendritic cell; PC, plasma cell.